Identifying Common Treatment Recommendations in Clear Cell Renal Cell Carcinoma
the Cancer Therapy Advisor take:
Heterogeneity of decision criteria was observed in most clinical scenarios comparing treatment algorithms in the treatment of metastatic clear cell renal cell carcinoma (mccRCC), according to an article published online in the journal The Oncologist.
The authors of this study aimed to obtain treatment algorithms and develop decision trees through the analysis of treatment of mccRCC from experts at 11 institutions.
Results showed the most common treatment recommendations for mccRCC included sunitinib, pazopanib, temsirolimus, interferon-α combined with bevacizumab, high-dose interleukin-2, sorafenib, axitinib, everolimus, and best supportive care.
Furthermore, the criteria relevant for treatment decision-making included performance status, Memorial Sloan-Kettering Cancer Center risk group, only or mainly lung metastases, cardiac insufficiency, hepatic insufficiency, age, and “zugzwang” (composite of multiple, related criteria).
The study’s findings demonstrate how available data, regarding decision criteria and different treatment strategies, are implemented distinctly among experts.
Heterogeneity of decision criteria was observed in most clinical scenarios in treatment of metastatic clear cell renal cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma